Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: One hundred and thirty two patients were randomized (stages: 38% IB, 10% IIA, 47% IIB, 5% pT3pN1; histology: 43% squamous, 57% non-squamous). The feasibility rates were 95.5% ( cisplatin and pemetrexed, CPx) and 75.4% ( cisplatin and vinorelbine, CVb) (P = 0.001); hematological G3/4 toxic effects were 10% (CPx) and 74% (CVb) (P < 0.001), non-hematological toxic effects were comparable (33% and 31%, P = 0.798). Delivery of total mean doses was 90% of planned with CPx, but 66% ( cisplatin) and 64% ( vinorelbine) with CVb (P < 0.0001). The median number of cycles [treatment time (weeks)] was 4 for CPx (11.2) and 3 for CVb (9.9). Time to withdrawal from therapy differed significantly between arms favoring CPx (P < 0.001). CONCLUSION:
Adjuvant chemotherapy with CPx is safe and feasible with less toxicity and superior dose delivery compared with CVb.
|
Authors | M Kreuter, J Vansteenkiste, J R Fischer, W Eberhardt, H Zabeck, J Kollmeier, M Serke, N Frickhofen, M Reck, W Engel-Riedel, S Neumann, M Thomeer, C Schumann, P De Leyn, T Graeter, G Stamatis, I Zuna, F Griesinger, M Thomas, TREAT investigators |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 24
Issue 4
Pg. 986-92
(Apr 2013)
ISSN: 1569-8041 [Electronic] England |
PMID | 23161898
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glutamates
- Pemetrexed
- Vinblastine
- Guanine
- Cisplatin
- Vinorelbine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Chemotherapy, Adjuvant
- Cisplatin
(administration & dosage, adverse effects)
- Disease-Free Survival
- Drug-Related Side Effects and Adverse Reactions
(chemically induced, pathology)
- Female
- Glutamates
(administration & dosage, adverse effects)
- Guanine
(administration & dosage, adverse effects, analogs & derivatives)
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Pemetrexed
- Survival Rate
- Vinblastine
(administration & dosage, adverse effects, analogs & derivatives)
- Vinorelbine
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|